GLP-1 drugs for weight loss are rapidly expanding worldwide, with Novo Nordisk's Wegovy® pill reaching over three million prescriptions since January 2026 and launching in the UAE and UK. Eli Lilly's investigational drug retatrutide shows significant weight loss and improvements in related conditions like osteoarthritis and sleep apnea. These drugs also show potential benefits for neurological, cardiovascular, and metabolic diseases. Lexaria Bioscience is advancing its DehydraTECH™ technology to improve oral delivery and reduce side effects of GLP-1 drugs, aiming to partner commercially as the market grows with forecasts reaching up to $180 billion by 2035.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
